Top

Journal of Assisted Reproduction and Genetics

Published in:

01-09-2008 | SHORT COMMUNICATION

Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist

Authors: Mustafa Bahceci, Ulun Ulug

Published in: Journal of Assisted Reproduction and Genetics | Issue 9-10/2008

Abstract

Purpose

This study evaluated the impact of route of progesterone administration as luteal phase support on the outcome of assisted conception cycles.

Methods

Intramuscular progesterone in oil (IMP) at 100 mg daily was administered to 903 women following oocyte retrieval whereas vaginal progesterone gel (VMP) at 90 mg was administered twice daily to 1,110 women. Retrospective analysis was performed according to the type of GnRH analogue used. Implantation (IR), clinical pregnancy (CPR) and biochemical pregnancy rates (BPR) were main outcomes.

Results

In GnRH agonist cycles, neither IR, CPR or BPR differed according to the route of progesterone. However, in GnRH antagonist cycles, IR and CPR were significantly lower in VMP group compared to IMP group. BPR also was significantly higher in VMP group compared to IMP group.

Conclusion

Our results suggest that route of progesterone administration for luteal phase support can be an important prognostic factor according to the type of GnRH analogue used for controlled ovarian hyperstimulation.

Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, Van Steirteghem A, Devroey P. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril. 1998;70:357–9. doi:10.1016/S0015-0282(98)00135-6.PubMedCrossRef

Kolibianakis EM, Devroey P. The luteal phase after ovarian stimulation. Reprod Biomed Online. 2002;5(Suppl):26–35.PubMed

Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians’ second choice? Data from the German national IVF registry. Hum Reprod. 2005;20:2373–5. doi:10.1093/humrep/dei086.PubMedCrossRef

Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Human Reproduction Update. 2007;13:581–90.PubMedCrossRef

Penzias AS. Luteal phase support. Fertil Steril. 2002;77:318–23. doi:10.1016/S0015-0282(01)02961-2.PubMedCrossRef

Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev. 2004;CD004830.

Levine H. Luteal support in IVF using the novel vaginal progesterone gel Crinone 8%: results of an open-label trial in 1,184 women from 16 US centers. Fertil Steril. 2000;74:836–7. doi:10.1016/S0015-0282(00)01497-7.PubMedCrossRef

Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95:403–6. doi:10.1016/S0029-7844(99)00542-6.PubMedCrossRef

Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril. 1994;62:485–90.PubMed

10.

Chantilis SJ, Zeitoun KM, Patel SI, Johns DA, Madziar VA, McIntire DD. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–9. doi:10.1016/S0015-0282(99)00362-3.PubMedCrossRef

11.

Damario MA, Goudas VT, Session DR, Hammitt DG, Dumesic DA. Crinone 8% vaginal progesterone gel results in lower embryonic implantation efficiency after in vitro fertilization-embryo transfer. Fertil Steril. 1999;72:830–6. doi:10.1016/S0015-0282(99)00364-7.PubMedCrossRef

12.

Propst AM, Hill JA, Ginsburg ES, Hurwitz S, Politch J, Yanushpolsky E. Randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization-embryo transfer cycles. Fertil Steril. 2001;76:1144–9. doi:10.1016/S0015-0282(01)02872-2.PubMedCrossRef

13.

Penzias AS, Alper MM. Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed Online. 2003;6:287–95.PubMedCrossRef

14.

Schoolcraft WB, Hesla JS, Gee MJ. Experience with progesterone gel for luteal support in a highly successful IVF programme. Hum Reprod. 2000;15:1284–8. doi:10.1093/humrep/15.6.1284.PubMedCrossRef

15.

Smitz J, Devroey P, Faguer B, Bourgain C, Camus M, Van Steirteghem AC. A randomized prospective study comparing supplementation of the luteal phase and early pregnancy by natural progesterone administered by intramuscular or vaginal route]: Reviews of (French). Gynecol Obstet (Paris). 1992;87:507–16.

16.

Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility. 2008;89:485–7.PubMedCrossRef

17.

Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002;17:2287–99. doi:10.1093/humrep/17.9.2287.PubMedCrossRef

18.

Dal Prato L, Bianchi L, Cattoli M, Tarozzi N, Flamigni N, Borini A. Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reprod Biomed Online. 2008;16:361–7.PubMed

19.

Ruan HC, Zhu XM, Luo Q, Liu AX, Qian YL, Zhou CY, Jin F, Huang HF, Sheng JZ. Ovarian stimulation with GnRH agonist, but not GnRH antagonist, partially restores the expression of endometrial integrin beta3 and leukaemia-inhibitory factor and improves uterine receptivity in mice. Hum Reprod. 2006;21:2521–9. doi:10.1093/humrep/del215.PubMedCrossRef

20.

Kumbak B, Ulug U, Erzik B, Akbas H, Bahceci M. Early clinical pregnancy loss rate in poor responder patients does not change compared to age-matched normoresponders. Fertil Steril. 2008.

21.

Bahceci M, Ulug U. Does underlying infertility aetiology impact on first trimester miscarriage rate following ICSI? A preliminary report from 1,244 singleton gestations. Hum Reprod. 2005;20:717–21. doi:10.1093/humrep/deh681.PubMedCrossRef

Title: Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist
Authors: Mustafa Bahceci
Ulun Ulug
Publication date: 01-09-2008
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 9-10/2008
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-008-9269-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9-10/2008

The effects of different concentrations of sodium selenite on the in vitro maturation of preantral follicles in serum-free and serum supplemented media

Stimulated intrauterine insemination (SIUI) and donor insemination (DI) as first line management for a selected subfertile population: the Manchester experience

Case report: Two successful pregnancies following the transfer of re-vitrified human day 7 blastocysts developed from vitrified cleaved embryos

Recombinant HCG for triggering ovulation increases the rate of mature oocytes in women treated for ICSI

Effect of GnRH down-regulation on cumulus cell viability and apoptosis as measured by fluorescence-activated cell sorting

Improvement in strategies for the non-invasive prenatal diagnosis of Huntington disease